Top-ranked stocks Wingstop (WING), Burlington Stores (BURL) and Prokidney CP (PROK) are likely to beat on the bottom line in their upcoming releases.

ProKidney Corp. (PROK) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could me...

There are many ways to approach penny stocks, but one that has gained popularity in recent years focuses on stocks in this category that are prime candidates for a “short squeeze.” A typical short squ...

ProKidney Corp. (NASDAQ:PROK ) Q3 2023 Results Conference Call November 14, 2023 8:00 AM ET Company Participants Dr. Glenn Schulman - SVP of IR Pablo Legorreta - Chairman of Board Dr. Tim Bertram - Co...

The heavy selling pressure might have exhausted for ProKidney Corp. (PROK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ana...

ProKidney Corp. (PROK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings est...

Shares of ProKidney (NASDAQ: PROK ) are in the green today, despite recent sales from special purpose acquisition company (SPAC) sponsor Chamath Palihapitiya. Back in July of 2022, ProKidney agreed to...

ProKidney focuses on therapies to treat chronic kidney disease (CKD). One of its top shareholders sold roughly $1.23 million worth of company stock.

Stock market investors are regularly monitoring highly shorted stocks, as the potential for an abrupt surge looms large.

A short squeeze is when traders who heavily short a stock start to cover their short positions by buying back the stock. This increases demand for the stock, and it pushes the price higher, forcing ot...

Here's a look at 3 biotech short squeeze candidates. For investors looking for short-term gains, technical analysis provides key insights on potential entry and exit points.

ProKidney Corp. has a noble goal - ending kidney dysfunction using cell therapy. It has produced some interesting data from a phase 2 trial.

Shares of ProKidney Corp. PROK, +9.57% rallied about 29% in premarket trading on Wednesday, the day after the company said preliminary data from a Phase 2 study found that the company's investigationa...

ProKidney entered into a definitive agreement to become a publicly-traded company via a business combination with Social Capital Suvretta Holdings Corp. III (Nasdaq: DNAC). These are the details.

ProKidney LP agreed to become a publicly-traded company via a business combination with Chamath Palihapitiya-backed special purpose acquisition company Social Capital Suvretta Holdings Corp III  (NASD...

ProKidney LP, a cellular therapeutics company focused on kidney disease, announced an agreement to merge with special purpose acquisition company (SPAC) Social Capital Suvretta Holdings Corp. III DNAC...

WINSTON-SALEM, N.C. & PALO ALTO, Calif.--(BUSINESS WIRE)--ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on chronic kidney disease (“CKD”), has entered into...

The 2022 year has started quietly for SPACs, with no deals announced in the first five trading days of the year. Although two new SPAC rumors have popped up since the market closed on Friday and both ...

BOSTON--(BUSINESS WIRE)--Schneider Electric, the leader in the digital transformation of energy management and automation, today announced a group of EcoXpert™ partners to achieve Master Level status ...